{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:13:12Z","timestamp":1792782792587,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi della Campania Luigi Vanvitelli","id":[{"id":"https:\/\/ror.org\/02kqnpp86","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We analysed adverse event reporting patterns associated with SSRIs using data from the European pharmacovigilance database, EudraVigilance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A descriptive analysis of individual case safety reports (ICSRs) was conducted between January 2020, 1st and December 2024, 31st. Disproportionality analysis were conducted for the two most frequently reported system organ classes (SOCs) and the three most frequently reported preferred terms (PTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During the study period, 21,665 ICSRs reporting at least one SSRI as suspected drug were retrieved. A total of 78,132 adverse events were identified, and sertraline (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200926,161; 33.5%) was the most reported SSRI. Most events were not serious, and the most reported criterion was Other Medically Important Condition (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200919,603; 25.1%). The most frequent outcome was \u201cUnknown\u201d (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200927,555). In the disproportionality analysis, for the SOC \u201cPsychiatric Disorders\u201d, escitalopram and fluvoxamine showed a higher disproportionate reporting (ROR 1.08; 95% CI 1.03\u20131.13; ROR 1.15; 95% CI 1.01\u20131.31, respectively). For the SOC \u201cNervous System Disorders\u201d, paroxetine showed a higher disproportionate reporting (ROR 1.10; 95% CI 1.04\u20131.16). Headache higher disproportionate reporting with sertraline (ROR 1.17; 95% CI 1.04\u20131.30), while dizziness with escitalopram (ROR 1.42; 95% CI 1.25\u20131.61), and somnolence with fluvoxamine and paroxetine (ROR 1.86; 95% CI 1.27\u20132.72; ROR 1.58; 95% CI 1.33\u20131.89, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SSRIs showed homogeneous adverse event reporting patterns, with relatively few differences in disproportional reporting between individual drugs. These results reinforce the importance of continuous pharmacovigilance monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00406-026-02378-9","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T08:31:15Z","timestamp":1789806675000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adverse event reporting patterns of selective serotonin reuptake inhibitors (SSRIs): disproportionality analysis using the European spontaneous reporting system"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8975-4019","authenticated-orcid":false,"given":"Ludovica Vittoria","family":"Laino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Mascolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Di Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"di Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giovanna","family":"Vastarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Rafaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"2378_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/PDS.1355","volume":"16","author":"MS McKenzie","year":"2007","unstructured":"McKenzie MS, McFarland BH (2007) Trends in antidepressant overdoses. Pharmacoepidemiol Drug Saf 16:513\u2013523. https:\/\/doi.org\/10.1002\/PDS.1355","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2378_CR2","doi-asserted-by":"publisher","unstructured":"Ogata N, de Souza Dantas LM, Crowell-Davis SL (2023) Selective serotonin reuptake inhibitors. Vet Psychopharmacol. https:\/\/doi.org\/10.1002\/9781119226253.ch8","DOI":"10.1002\/9781119226253.ch8"},{"key":"2378_CR3","unstructured":"AIFA Paroxetina, Riassunto delle Caratteristiche del Prodotto (RCP). https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=paroxetina&spellingCorrection=true. Accessed 21 Nov 2025"},{"key":"2378_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/JECH-2020-214611","volume":"75","author":"MP Hengartner","year":"2021","unstructured":"Hengartner MP, Amendola S, Kaminski JA et al (2021) Suicide risk with selective serotonin reuptake inhibitors and other new-generation antidepressants in adults: a systematic review and meta-analysis of observational studies. J Epidemiol Community Health 75:523\u2013530. https:\/\/doi.org\/10.1136\/JECH-2020-214611","journal-title":"J Epidemiol Community Health"},{"key":"2378_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/S00228-023-03596-Z","volume":"80","author":"C Elli","year":"2024","unstructured":"Elli C, Novella A, Pasina L (2024) Serotonin syndrome: a pharmacovigilance comparative study of drugs affecting serotonin levels. Eur J Clin Pharmacol 80:231\u2013237. https:\/\/doi.org\/10.1007\/S00228-023-03596-Z","journal-title":"Eur J Clin Pharmacol"},{"key":"2378_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/J.PSYCHRES.2023.115300","volume":"326","author":"Y Chen","year":"2023","unstructured":"Chen Y, Fan Q, Liu Y et al (2023) Cardiovascular toxicity induced by SSRIs: analysis of spontaneous reports submitted to FAERS. Psychiatry Res 326:115300. https:\/\/doi.org\/10.1016\/J.PSYCHRES.2023.115300","journal-title":"Psychiatry Res"},{"key":"2378_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/S12991-023-00447-0","author":"J Ben-Sheetrit","year":"2023","unstructured":"Ben-Sheetrit J, Hermon Y, Birkenfeld S et al (2023) Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants. Ann Gen Psychiatry. https:\/\/doi.org\/10.1186\/S12991-023-00447-0","journal-title":"Ann Gen Psychiatry"},{"key":"2378_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jpsychires.2018.10.021","volume":"107","author":"K El Asmar","year":"2018","unstructured":"El Asmar K, F\u00e8ve B, Colle R et al (2018) Early weight gain predicts later metabolic syndrome in depressed patients treated with antidepressants: findings from the METADAP cohort. J Psychiatr Res 107:120\u2013127. https:\/\/doi.org\/10.1016\/j.jpsychires.2018.10.021","journal-title":"J Psychiatr Res"},{"key":"2378_CR9","doi-asserted-by":"publisher","DOI":"10.4081\/JPHR.2021.2203\/ASSET\/IMAGES\/LARGE\/10.4081_JPHR.2021.2203-FIG1.JPEG","author":"HK Allam","year":"2021","unstructured":"Allam HK, Helmy MS, Badry AS, El, Younis FE (2021) Workaholism, sleep disorders, and potential e-learning impacts among Menoufia University staff during COVID-19 pandemic. J Public Health Res. https:\/\/doi.org\/10.4081\/JPHR.2021.2203\/ASSET\/IMAGES\/LARGE\/10.4081_JPHR.2021.2203-FIG1.JPEG","journal-title":"J Public Health Res"},{"key":"2378_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/J.SCITOTENV.2022.154656","author":"N Diaz-Camal","year":"2022","unstructured":"Diaz-Camal N, Cardoso-Vera JD, Islas-Flores H et al (2022) Consumption and ocurrence of antidepressants (SSRIs) in pre- and post-COVID-19 pandemic, their environmental impact and innovative removal methods: a review. Sci Total Environ. https:\/\/doi.org\/10.1016\/J.SCITOTENV.2022.154656","journal-title":"Sci Total Environ"},{"key":"2378_CR11","unstructured":"AIFA pubblica il Rapporto Nazionale (2022) L\u2019uso dei Farmaci in Italia. https:\/\/www.aifa.gov.it\/-\/aifa-pubblica-rapporto-osmed-2022ci-in-italia. Accessed 17 Sep 2025"},{"key":"2378_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/S40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B et al (2024) The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): explanation and elaboration. Drug Saf 47:585\u2013599. https:\/\/doi.org\/10.1007\/S40264-024-01423-7","journal-title":"Drug Saf"},{"key":"2378_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/PH16111566","author":"L Sportiello","year":"2023","unstructured":"Sportiello L, Di Napoli R, Balzano N et al (2023) Disease-modifying therapies (DMTs) in pregnant and lactating women with multiple sclerosis: analysis of real-world data from EudraVigilance database. Pharm (Basel). https:\/\/doi.org\/10.3390\/PH16111566","journal-title":"Pharmaceuticals (Basel)"},{"key":"2378_CR14","unstructured":"MedDRA https:\/\/www.meddra.org\/how-to-use\/support-documentation\/italian\/welcome. Accessed 18 Sep 2025"},{"key":"2378_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/BIB\/BBAB347","author":"Y Noguchi","year":"2021","unstructured":"Noguchi Y, Tachi T, Teramachi H (2021) Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform. https:\/\/doi.org\/10.1093\/BIB\/BBAB347","journal-title":"Brief Bioinform"},{"key":"2378_CR16","unstructured":"European Medicines Agency screening for adverse reactions in EudraVigilance. www.ema.europa.eu\/contact. Accessed 4 Aug 2026"},{"key":"2378_CR17","unstructured":"Shreffler J, Huecker MR (2023) Hypothesis testing, P values, confidence intervals, and significance. StatPearls"},{"key":"2378_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/HEALTHCARE13101174","volume":"13","author":"J Samard\u017ei\u0107","year":"2025","unstructured":"Samard\u017ei\u0107 J, Simovi\u0107 F, Sekani\u0107 K, Brankovi\u0107 M (2025) Five-year trends in SSRI consumption: a precision medicine approach to comparative analysis between Serbia and European countries. Healthcare (Basel) 13:1174. https:\/\/doi.org\/10.3390\/HEALTHCARE13101174","journal-title":"Healthcare (Basel)"},{"key":"2378_CR19","unstructured":"AIFA (2023) l\u2019uso dei farmaci in Italia rapporto nazionale 2022"},{"key":"2378_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/FPSYG.2022.1052702","author":"J Tang","year":"2022","unstructured":"Tang J, Zhang T (2022) Causes of the male-female ratio of depression based on the psychosocial factors. Front Psychol. https:\/\/doi.org\/10.3389\/FPSYG.2022.1052702","journal-title":"Front Psychol"},{"key":"2378_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/S12939-024-02320-2","author":"A Bacigalupe","year":"2024","unstructured":"Bacigalupe A, Mart\u00edn U, Triolo F et al (2024) Is the diagnosis and treatment of depression gender-biased? Evidence from a population-based aging cohort in Sweden. Int J Equity Health. https:\/\/doi.org\/10.1186\/S12939-024-02320-2","journal-title":"Int J Equity Health"},{"key":"2378_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/S40264-020-01021-3\/TABLES\/7","volume":"44","author":"G di Mauro","year":"2021","unstructured":"di Mauro G, Zinzi A, Scavone C et al (2021) PCSK9 inhibitors and neurocognitive adverse drug reactions: analysis of individual case safety reports from the eudravigilance database. Drug Saf 44:337\u2013349. https:\/\/doi.org\/10.1007\/S40264-020-01021-3\/TABLES\/7","journal-title":"Drug Saf"},{"key":"2378_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/21556660.2019.1566137","volume":"8","author":"M Uberra","year":"2019","unstructured":"Uberra M, G\u20ac D, Ekmekci PE (2019) Healthcare professionals\u2019 pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates. J Drug Assess 8:13\u201320. https:\/\/doi.org\/10.1080\/21556660.2019.1566137","journal-title":"J Drug Assess"},{"key":"2378_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8690546","author":"B Kassa Alemu","year":"2019","unstructured":"Kassa Alemu B, Biru TT (2019) Health care professionals\u2019 knowledge, attitude, and practice towards adverse drug reaction reporting and associated factors at selected public hospitals in Northeast Ethiopia: a cross-sectional study. BioMed Res Int. https:\/\/doi.org\/10.1155\/2019\/8690546","journal-title":"BioMed Res Int"},{"key":"2378_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/2050-6511-14-16","volume":"14","author":"S Kc","year":"2013","unstructured":"Kc S, Tragulpiankit P, Gorsanan S, Edwards IR (2013) Attitudes among healthcare professionals to the reporting of adverse drug reactions in Nepal. BMC Pharmacol Toxicol 14:16. https:\/\/doi.org\/10.1186\/2050-6511-14-16","journal-title":"BMC Pharmacol Toxicol"},{"key":"2378_CR26","unstructured":"Medicines Agency E (2017) Guideline on good pharmacovigilance practices (GVP) - module VI \u2013 collection, management and submission of reports of suspected adverse reactions to medicinal products (rev 2)"},{"key":"2378_CR27","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.120942","author":"C Mazzitello","year":"2013","unstructured":"Mazzitello C, Esposito S, De Francesco A et al (2013) Pharmacovigilance in Italy: an overview. J Pharmacol Pharmacother. https:\/\/doi.org\/10.4103\/0976-500X.120942","journal-title":"J Pharmacol Pharmacother"},{"key":"2378_CR28","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/S40264-017-0572-8","volume":"40","author":"A Santoro","year":"2017","unstructured":"Santoro A, Genov G, Spooner A et al (2017) Promoting and protecting public health: how the European Union pharmacovigilance system works. Drug Saf 40:855\u2013869. https:\/\/doi.org\/10.1007\/S40264-017-0572-8","journal-title":"Drug Saf"},{"key":"2378_CR29","doi-asserted-by":"publisher","unstructured":"Nicoletti MM, Anatriello A, Liguori V et al (2023) Skin toxicities associated with botulin toxin injection for aesthetic procedures: data from the european spontaneous reporting system. Pharm (Basel). https:\/\/doi.org\/10.3390\/PH16111611","DOI":"10.3390\/PH16111611"},{"key":"2378_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/NEUROLINT13030038","volume":"13","author":"AN Edinoff","year":"2021","unstructured":"Edinoff AN, Akuly HA, Hanna TA et al (2021) Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int 13:387\u2013401. https:\/\/doi.org\/10.3390\/NEUROLINT13030038","journal-title":"Neurol Int"},{"key":"2378_CR31","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/ACPS.13817","volume":"152","author":"DF Papolos","year":"2025","unstructured":"Papolos DF, Teicher MH, Post RM (2025) Treatment of early-onset specified and unspecified bipolar disorders: a systematic review and strategies for identifying and managing a thermally dysregulated subtype in children. Acta Psychiatr Scand 152:156\u2013179. https:\/\/doi.org\/10.1111\/ACPS.13817","journal-title":"Acta Psychiatr Scand"},{"key":"2378_CR32","unstructured":"AIFA Fluoxetina, Riassunto delle Caratteristiche del Prodotto (RCP). https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=fluoxetina&spellingCorrection=true. Accessed 21 Nov 2025"},{"key":"2378_CR33","unstructured":"AIFA Fluvoxamina, Riassunto delle Caratteristiche del Prodotto (RCP). https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=fluvoxamina&spellingCorrection=true. Accessed 21 Nov 2025"},{"key":"2378_CR34","unstructured":"AIFA Sertralina, Riassunto delle Caratteristiche del Prodotto (RCP). https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=SERTRALINA%20(PRINCIPIO%20ATTIVO)&exact=true. Accessed 21 Nov 2025"},{"key":"2378_CR35","unstructured":"AIFA Escitalopram, Riassunto delle Caratteristiche del Prodotto (RCP). https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=escitalopram&spellingCorrection=true. Accessed 21 Nov 2025"},{"key":"2378_CR36","unstructured":"AIFA Citalopram, Riassunto delle Caratteristiche del Prodotto (RCP). https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=citalopram&spellingCorrection=true. Accessed 21 Nov 2025"},{"key":"2378_CR37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/J.JAD.2018.04.047","volume":"236","author":"S Telang","year":"2018","unstructured":"Telang S, Walton C, Olten B, Bloch MH (2018) Meta-analysis: second generation antidepressants and headache. J Affect Disord 236:60\u201368. https:\/\/doi.org\/10.1016\/J.JAD.2018.04.047","journal-title":"J Affect Disord"},{"key":"2378_CR38","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1111\/JGS.13395","volume":"63","author":"K Thorlund","year":"2015","unstructured":"Thorlund K, Druyts E, Wu P et al (2015) Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc 63:1002\u20131009. https:\/\/doi.org\/10.1111\/JGS.13395","journal-title":"J Am Geriatr Soc"},{"key":"2378_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/SLEEP\/ZSAD177","author":"S Zhou","year":"2023","unstructured":"Zhou S, Li P, Lv X et al (2023) Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis. Sleep. https:\/\/doi.org\/10.1093\/SLEEP\/ZSAD177","journal-title":"Sleep"},{"key":"2378_CR40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00004714-199902000-00013","volume":"19","author":"RC Rosen","year":"1999","unstructured":"Rosen RC, Lane RM, Menza M (1999) Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 19:67\u201385. https:\/\/doi.org\/10.1097\/00004714-199902000-00013","journal-title":"J Clin Psychopharmacol"},{"key":"2378_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4088\/PCC.V03N0105","volume":"3","author":"JM Ferguson","year":"2001","unstructured":"Ferguson JM (2001) SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 3:22\u201327. https:\/\/doi.org\/10.4088\/PCC.V03N0105","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"2378_CR42","doi-asserted-by":"publisher","first-page":"1464898","DOI":"10.3389\/FPSYT.2024.1464898\/BIBTEX","volume":"15","author":"C Lassale","year":"2024","unstructured":"Lassale C, Lugon G, Hern\u00e1ez \u00c1 et al (2024) Trajectories of antidepressant use and 6-year change in body weight: a prospective population-based cohort study. Front Psychiatry 15:1464898. https:\/\/doi.org\/10.3389\/FPSYT.2024.1464898\/BIBTEX","journal-title":"Front Psychiatry"},{"key":"2378_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPEN-2017-016224","volume":"7","author":"Z Shi","year":"2017","unstructured":"Shi Z, Atlantis E, Taylor AW et al (2017) SSRI antidepressant use potentiates weight gain in the context of unhealthy lifestyles: results from a 4-year Australian follow-up study. BMJ Open 7:e016224. https:\/\/doi.org\/10.1136\/BMJOPEN-2017-016224","journal-title":"BMJ Open"},{"key":"2378_CR44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/15563650.2022.2151455","volume":"61","author":"J Cooper","year":"2023","unstructured":"Cooper J, Duffull SB, Isbister GK (2023) Predicting serotonin toxicity in serotonin reuptake inhibitor overdose. Clin Toxicol 61:22\u201328. https:\/\/doi.org\/10.1080\/15563650.2022.2151455","journal-title":"Clin Toxicol"},{"key":"2378_CR45","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/2042098618772979","volume":"9","author":"MP Rochester","year":"2018","unstructured":"Rochester MP, Kane AM, Linnebur SA, Fixen DR (2018) Evaluating the risk of QTc prolongation associated with antidepressant use in older adults: a review of the evidence. Ther Adv Drug Saf 9:297. https:\/\/doi.org\/10.1177\/2042098618772979","journal-title":"Ther Adv Drug Saf"},{"key":"2378_CR46","doi-asserted-by":"crossref","unstructured":"Murphy LR, PharmD, BCPS B, Choi S, Bostwick JR, PharmD, BCPS B (2018) QT prolongation and antidepressants 35(3)","DOI":"10.5055\/jom.2018.0427"},{"key":"2378_CR47","doi-asserted-by":"publisher","unstructured":"Malik M, Camm AJ (2012) Evaluation of drug-induced QT interval prolongation. Drug Safety 24(5):323\u2013351. https:\/\/doi.org\/10.2165\/00002018-200124050-00001","DOI":"10.2165\/00002018-200124050-00001"},{"key":"2378_CR48","doi-asserted-by":"publisher","unstructured":"Belagaje SR, Brahmbhatt D, Abramoff BA (2023) Selective serotonin reuptake inhibitors. Ischem Stroke Ther Compr Guide. https:\/\/doi.org\/10.1007\/978-3-031-49963-0_23","DOI":"10.1007\/978-3-031-49963-0_23"},{"key":"2378_CR49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/978-3-319-50174-1_11\/TABLES\/1","volume":"964","author":"Y Albayrak","year":"2017","unstructured":"Albayrak Y, Hashimoto K (2017) Sigma-1 receptor agonists and their clinical implications in neuropsychiatric disorders. Adv Exp Med Biol 964:153\u2013161. https:\/\/doi.org\/10.1007\/978-3-319-50174-1_11\/TABLES\/1","journal-title":"Adv Exp Med Biol"},{"key":"2378_CR50","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/S00210-026-05145-8","volume":"399","author":"R Di Napoli","year":"2026","unstructured":"Di Napoli R, Mascolo A, Balzano N et al (2026) Safety profile of fentanyl with different routes of administration: a disproportionality analysis using the EudraVigilance database. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 399:8. https:\/\/doi.org\/10.1007\/S00210-026-05145-8","journal-title":"Naunyn-Schmiedeberg\u2019s Archives Pharmacol 2026"},{"issue":"1","key":"2378_CR51","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/S40264-024-01473-X","volume":"48","author":"Y Noguchi","year":"2024","unstructured":"Noguchi Y, Tachi T, Yoshimura T (2024) Caveats of covariate adjustment in disproportionality analysis for best practices. Drug Saf 48(1):48-1\u20135. https:\/\/doi.org\/10.1007\/S40264-024-01473-X","journal-title":"Drug Saf"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-026-02378-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-026-02378-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-026-02378-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T08:31:20Z","timestamp":1789806680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-026-02378-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":51,"alternative-id":["2378"],"URL":"https:\/\/doi.org\/10.1007\/s00406-026-02378-9","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this study relied exclusively on anonymised, aggregated data from spontaneous reports in the EudraVigilance database, it did not require ethical approval. This information was collected for regulatory and public health purposes and involved no direct intervention with individuals. Access to the data followed the standard EudraVigilance policy and no further authorisation was required. No identifiable patient information was used or disclosed.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}